Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit US$ 22.14 Min. order: 1 piece ★★★★★ 4.7 (164 reviews) Sold : Login>>
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity US$ 25.14 Min. order: 1 piece ★★★★★ 4.3 (26 reviews) Sold : Login>>
Eloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept - Bhattachar - 2026 - Diabetes, Obesity and Metabolism US$ 26.16 Min. order: 1 piece ★★★★★ 4.4 (252 reviews) Sold : Login>>
Cagrilintide is a novel, long-acting peptide designed to target multiple receptors involved in appetite regulation and energy balance. Unlike traditional weight loss medications that often target a single pathway, cagrilintide acts as US$ 22.81 Min. order: 1 piece ★★★★★ 4.6 (47 reviews) Sold : Login>>
Novo's Phase 3 CagriSema results disappoint analysts, sending stock tumbling - MM+M US$ 21.29 Min. order: 1 piece ★★★★★ 4.4 (11 reviews) Sold : Login>>